Geneva-based Addex Therapeutics Ltd. completed a CHF40 million capital offering.
The company issued 13,037,577 new shares at CHF3.13 apiece.
Addex intends to use the proceeds to develop its portfolio of drug candidates, including registration studies for lead program dipraglurant, a treatment for Parkinson's disease.